COMMUNIQUÉS West-GlobeNewswire

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
01/09/2024
Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE [...]
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
01/09/2024
Data from Integrated Safety Analysis Across Three Clinical Trials Reinforces Robust Safety Profile of Aficamten Analysis from FOREST-HCM Demonstrates Successful Withdrawal of Standard of Care Medications in Patients [...]
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
01/09/2024
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodeling by Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography, Symptom Relief and Improvement in Biomarkers with Aficamten [...]
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
31/08/2024
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials testing multi- [...]
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
31/08/2024
SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Avricore Grants Options
31/08/2024
VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ Avricore ”) today announces that the Company’s board of directors has approved the granting of stock [...]
Vision Sensing Acquisition Corp. Announces Intention to Extend the Period to Consummate Its Initial Business Combination to October 3, 2024
30/08/2024
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ”) a special purpose acquisition company, announced today that it has notified Continental Stock [...]
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
30/08/2024
Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients SAN DIEGO and TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences [...]
Jushi Holdings Inc. Announces Filing of Canadian Preliminary Base Shelf Prospectus
30/08/2024
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES BOCA RATON, Fla., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) (OTCQX: [...]
Receipt of Nasdaq Delisting Determination - Plans to Appeal
30/08/2024
August 30, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Receipt of Nasdaq Delisting Determination Plans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage [...]
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update
30/08/2024
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company [...]
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
30/08/2024
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee [...]
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
30/08/2024
- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications - No new safety signals observed at [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
30/08/2024
Company announcement – No. 43 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August [...]
Fagron’s share buy-back program: Weekly update
30/08/2024
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 August 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 26 August 2024 through 30 August 2024, Fagron purchased 37 [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
30/08/2024
Please see enclosed pdf. Attachment 30082024_trading_in_shares_PRM
Total number of shares and voting rights in Zealand Pharma on August 30, 2024
30/08/2024
Company announcement – No. 42 / 2024 Total number of shares and voting rights in Zealand Pharma on August 30, 2024 Copenhagen, Denmark, August 30, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 [...]
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
30/08/2024
- In participants who switched from tafamidis and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum transthyretin (TTR) at Month 1 of the [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
30/08/2024
Please see enclosed pdf. Attachment 30082024_trading_in_shares_ARA

Pages